Suspension component-specific triamcinolone and moxifloxacin compositions and associated methods of use
US11446242B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Mar 3, 2022 |
| Grant date | Sep 20, 2022 |
| Priority date | — |
| Expiry date | Mar 3, 2042 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P31/04
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided here are new ophthalmologically suitable pharmaceutical compositions comprising an effective amount of a moxifloxacin compound and an effective amount of a triamcinolone compound and a suspension component comprising a polysorbate, hyaluronic acid, or both. In aspects, the compositions are stable suspensions maintaining physical stability and chemical stability for extended periods of time (e.g., exhibiting no sustained flocculation, coagulation, or clumping after several months of storage under typical storage conditions). In aspects, the compositions comprise a non-ionic surfactant or, e.g., a non-ionic suspension agent providing both surfactant and suspension functionality. In aspects, such compositions further comprise an effective amount of a chelating agent/component. Further described are related compositions and methods of making and using such compositions, e.g., in the treatment of eye infections.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.